37 results about "Serum phosphate" patented technology

The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

Disclosed herein are FGF23 c-tail fusion proteins, pharmaceutical compositions comprising the FGF23 c-tail fusion proteins, and methods of treatment using the FGF23 c-tail fusion proteins. This application discloses fusion proteins comprising a FGF-23 c-tail protein fused to a heterologous amino acid sequence, wherein said fusion protein modulates serum phosphate levels but does not substantially modulate serum 1, 25 VitD levels. In some embodiments, the FGF-23 c-tail protein is fused to the heterologous amino acid sequence via a linker. This invention also encompasses vectors comprising the nucleic acids disclosed herein, and a host cell comprising the vector or polynucleotides encoding the proteins of the invention.

The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical -grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

The invention provides a serum phosphate adsorbing agent; a hydrophilic carrier is immobilized by ligands capable of capturing phosphate ions to obtain the serum phosphate adsorbing agent; the hydrophilic carrier is selected from one or more out of cellulose, agarose and polyvinyl alcohol microsphere, and the ligands capable of capturing phosphate ions refer to amino polymers. The invention also provides a preparation method of the serum phosphate adsorbing agent and an adsorption column for blood perfusion, prepared by the serum phosphate adsorbing agent. Compared with medicines which are orally taken to act on the human body, the serum phosphate adsorbing agent can directly remove the phosphate ions in blood through blood circulation, so as to immediately alleviate the illness state of a patient; and the serum phosphate adsorbing agent can be combined with hemodialysis, oral taking pain of the patient each day can be reduced, and the result caused by a situation that the patient forgets to take the medicine can be avoided.

The invention discloses self-expanding composite bone cement and a preparation method thereof. The self-expanding composite bone cement is prepared by mixing a solid-phase component and a liquid-phasecomponent according to a mass-volume ratio of (1g: 1.5 ml) to (1g: 7.2 ml); wherein the solid phase is prepared from the following raw materials in percentage by mass: 30%-70% of polymethyl methacrylate-acrylic acid-anhydrous calcium hydrophosphate copolymer microspheres, 15%-35% of anhydrous calcium hydrophosphate and 15%-35% of tetracalcium phosphate, and the sum of the mass percentages of thecomponents is 100%; and the bone cement liquid phase is any one of distilled water, blood, normal saline, dilute acid, serum and phosphate solution. The prepared self-expanding composite bone cement has high water absorption expansion rate and good mechanical properties, and is expected to become promising bone cement for clinical application.

A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

The invention provides a phosphate binder and a preparation method thereof and in particular provides a method for preparing the phosphate binder. The method comprises the following steps: (i) providing a mixed solution, wherein the mixed solution comprises (a) a carbohydrate; (b) citric acid, citrate, carbonate or a combination thereof, and (c) water; and (ii) adding an iron salt and an insoluble solvent into the mixed solution under alkaline conditions, producing a precipitate, and separating the precipitate, thereby obtaining the phosphate binder, wherein the pH value of the alkaline condition is 4-13. According to the method disclosed by the invention, the phosphate binder is capable of obviously reducing the serum phosphate concentration.

A pharmaceutical preparation including an amino acid infusion fluid is administered to patients receiving dialysis to ameliorate nutritional status of patients. As a result, anemia can be ameliorated and the required dose of erythropoietin can be reduced in these patients. Furthermore, the serum phosphate levels can be controlled to a predetermined range and protein catabolism can be suppressed in such patients. The amino acid infusion fluid has at least one essential amino acid. The preferred amino acid composition includes at least L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, L-valine, L-alanine, L-arginine, L-aspartic acid, L-glutamic acid, L-histidine, L-proline, L-serine, L-tyrosine, glycine and L-cysteine, wherein the ratio of essential amino acids to non-essential amino acids is 2.5 or higher.

The invention provides a method for improving the sperm motility and increasing an in-vitro-fertilization rate of frozen bovine semen by the aid of genistein. The method is particularly characterized in that the genistein containing 1%o of DMSO (dimethyl sulfoxide) is added into SP-TALP (serum phosphate-total alkaline phosphatase) washing liquid for washing the frozen bovine semen in earlier-stage processing for the frozen bovine semen, or mixed liquid of PHE (phenylalanine) capacitation liquid and IVF-TALP (in vitro fertilization-total alkaline phosphatase) fertilization liquid containing bovine semen in a capacitation processing stage of second-stage pre-fertilization semen or prepared fertilization drops containing oocytes in a third-stage in-vitro-fertilization procedure; the added amounts of the genistein in two earlier stages of a fertilization procedure of each bottle of frozen bovine semen are 10 micromoles per liter, and the final concentration of the genistein in mixed liquid of the bovine semen and the fertilization drops containing the oocytes is 10 micromoles per liter when the genistein is added in a third stage of the fertilization procedure of each bottle of frozen bovine semen. The method has the advantages that the genistein is respectively used in the three in-vitro-fertilization stages, so that the sperm motility is greatly improved, and the sperm fertilization rate is greatly increased.

A method for reducing phosphate absorption in a human or non-human animal subject at risk of developing or having developed hyperphosphatemia is disclosed. The method includes the step of administering orally to the subject an anti-intestinal sodium phosphate cotransporter type 2B (Npt2B) antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

The invention discloses health-care granules for preventing the negative balance of energy metabolism of cows and a using method of the health-care granules. The health-care granules disclosed by the invention are mainly prepared from the following raw materials: calcium propionate, brown sugar, magnesium chloride, yeast, sodium chloride and corn flour. The health-care granules for feeding the cows, disclosed by the invention, have the advantages of being convenient to use, low in cost, good in palatability, notable in effects and the like. After the postnatal cows are fed with the health-care granules, physical strength can be quickly restored, the quantity of rumen microbial populations can be maintained, the food consumption is restored, the milk yield is increased, and the ability of resisting diseases is improved. Feeding experiments for the postnatal cows confirm that the health-care granules can effectively maintain the level of blood calcium (Ga), serum phosphate (P), blood magnesium (Mg) and blood sugar (GLU), and can reduce the level of beta-hydroxybutyric acid (BHBA), free fatty acid (NEFA), and aspartate aminotransferase (AST). The attack rate of nutrient metabolic disease-ketosis of the postnatal cows can be effectively reduced.

The present invention provides improved methods and compositions for therapeutically controlling and / or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrocitrate, hydrochloride, hydrobromide, hydroacetate or hydroanionic form.

The invention provides an iron-based hydroxide-low molecular weight sugar phosphate binder as well as a preparation method and application thereof. Specifically, the invention provides a phosphate binder which comprises an iron-based hydroxide and low molecular weight sugar, wherein the number of monosaccharide units of the low molecular weight sugar is 3-20, and based on the total weight of the phosphate binder, the mass ratio of the iron is 2-45wt%. Experiments prove that the phosphate binder has an obvious effect of lowering the serum phosphate level. Therefore, the phosphate binder has wide application prospects.

The invention relates to a medicine composite injection for treating osteoporosis and a preparation method thereof. In particular, active constituents of the injection comprise one or more constituents out of teriparatide combined with bisphosphonate series, calcitonin series and estrogen, and besides, pH regulating agents and excipient with the amount acceptable to pharmacy are added. According to the preparation method, the preparation process is investigated, the rat urinary calcium content, the blood calcium conent, the serum phosphate content and the thighbone mineral matter content further serve as indexes, the treatment effect of the injection on osteoporosis model rats is further investigated, the prepared composite injection is remarkable in effect, and the practical significance is achieved.

The present invention discloses pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

The invention provides an iron-based hydroxide-degraded carbohydrate phosphate binder as well as a preparation method and application thereof. Specifically, the invention provides a phosphate binder which comprises an iron-based hydroxide and a degraded carbohydrate, wherein based on the total weight of the phosphate binder, the mass ratio of the iron is 5-45wt%; the number-average molecular weight of the degraded carbohydrate is 1000-300000Da; and a ratio (D1 / D2) of the number-average molecular weight D1 of the degraded carbohydrate to a number-average molecular weight D2 of the carbohydrate before degradation is 0.05-0.8. Experiments prove that the phosphate binder has an obvious effect of lowering the serum phosphate level. Therefore, the phosphate binder has wide application prospects.

It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-phytic acid (C6H6[OPO(OH)2]o) antibody or an anti-phytate antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

The present invention provides compositions and methods for treating a hypophosphatemic disorder, such as X-linked hypophosphatemia (XLH). The method entails administering to a subject a pharmaceutical composition containing an anti-FGF23 ligand, wherein the dosing regimen of the pharmaceutical is designed to reach effective and efficient control of FGF23 activity.

Combinations of oxylanthanum carbonate and tenapanor for reducing serum phosphate levels in patients with end-stage renal disease (ESRD) and / or chronic kidney disease (CKD).

The invention relates to a phosphate adsorption composite nanomaterial as well as preparation and an application thereof. The composite nanomaterial comprises a nano-carrier and Sevelamer carbonate in the mass ratio being (3-12):1, wherein the nano-carrier comprises lipidosome, and Sevelamer carbonate is polymer carbonate of 2-propen-1-amine and epoxy chloropropane. The phosphate adsorption nano-composite material is used for preparing a medicine for reducing serum phosphate. Compared with the prior art, the excellent adsorption performance of polymer carbonate of 2-propen-1-amine and epoxy chloropropane is sufficiently utilized, the advantages that the long-circulation nano-carrier is non-toxic, stable and not easily captured by a phagocytic system in a body are played, and the high-biocompatibility lipidosome / Sevelamer composite nanomaterial easy to excrete is prepared. The method adopts a simple preparation process and easily controllable conditions and is thus suitable for clinic treatment of intractable hyperphosphatemia.

The present invention provides improved methods and compositions for therapeutically controlling and / or reducing serum phosphate levels in animals and mammalian patients. The methods comprise administering to the patient an amount of a dendrimer composition effective to prevent absorption of substantial amounts of phosphate from the patient's GI tract. In a preferred version, a dose of between 2.5 and 15 grams per day is effective to prevent over 80% of phosphate present in the patient's GI tract from being absorbed. The dendrimer composition may comprise a hydrochloride, hydrobromide, hydroacetate or hydroanionic form.

The invention relates to a phosphate adsorption composite nanomaterial as well as preparation and an application thereof. The composite nanomaterial comprises a nano-carrier and Sevelamer carbonate in the mass ratio being (3-12):1, wherein the nano-carrier comprises lipidosome, and Sevelamer carbonate is polymer carbonate of 2-propen-1-amine and epoxy chloropropane. The phosphate adsorption nano-composite material is used for preparing a medicine for reducing serum phosphate. Compared with the prior art, the excellent adsorption performance of polymer carbonate of 2-propen-1-amine and epoxy chloropropane is sufficiently utilized, the advantages that the long-circulation nano-carrier is non-toxic, stable and not easily captured by a phagocytic system in a body are played, and the high-biocompatibility lipidosome / Sevelamer composite nanomaterial easy to excrete is prepared. The method adopts a simple preparation process and easily controllable conditions and is thus suitable for clinic treatment of intractable hyperphosphatemia.

The invention discloses a medicament for treating fracture and a preparation method thereof. The medicament is prepared by traditional Chinese medicine raw materials such as rhizome drynariae, pyrite, corydalis tuber, notoginseng, turmeric, libanotus, myrrh, dragon's blood, sandalwood, dalbergia wood and eaglewood. The medicament can tonify the kidney and strengthen bone, rejoin muscle and ligament, relieve bruises, relieve injury and stop pain, relax tendons, invigorate blood circulation, promote the bone to absorb calcium and improve levels of blood calcium and serum phosphate, is favorable for calcification and sclerotin formation of the bone, and can also improve the function of chondrocyte, postpone degenerative change of cells, reduce pathological change rate of arthrosis, and promote proliferation of netlike cells and haemoglobin in the peripheral blood of the bone marrow; and compared with the various existing orthopedics medicaments, the medicament can better promote poroma proliferation and accelerate fracture healing, has no toxic side effects, can be used by patients from any age group, has no adverse reaction report by now, and has superior curative effect.

The invention provides a serum phosphate adsorbing agent; a hydrophilic carrier is immobilized by ligands capable of capturing phosphate ions to obtain the serum phosphate adsorbing agent; the hydrophilic carrier is selected from one or more out of cellulose, agarose and polyvinyl alcohol microsphere, and the ligands capable of capturing phosphate ions refer to amino polymers. The invention also provides a preparation method of the serum phosphate adsorbing agent and an adsorption column for blood perfusion, prepared by the serum phosphate adsorbing agent. Compared with medicines which are orally taken to act on the human body, the serum phosphate adsorbing agent can directly remove the phosphate ions in blood through blood circulation, so as to immediately alleviate the illness state of a patient; and the serum phosphate adsorbing agent can be combined with hemodialysis, oral taking pain of the patient each day can be reduced, and the result caused by a situation that the patient forgets to take the medicine can be avoided.

A method for reducing serum phosphate in a subject in need thereof comprising administering once per day to said subject a phosphate binder, wherein the phosphate binder has a phosphate binding capacity of at least 52 mmole.